PV Bulletin
PvBulletin
Home /Country Guides/UK MHRA refreshes PV procedures and adds decentralised manufacture UK GVP
Country GuidesMhra

UK MHRA refreshes PV procedures and adds decentralised manufacture UK GVP

MHRA updated UK PV procedures (8 Jan 2025), published decentralised manufacture UK GVP (10 Jun 2025), and maintains UK modifications to EU GVP PDFs for UK MAHs.

PV Impact Brief

Urgency: HighConfidence: medium
Relevant for
Local Safety OfficerSignal Management LeadRegulatory Intelligence LeadPV Operations LeadPV Quality LeadPV Technology / CSV LeadAggregate Reports LeadQPPV
Processes impacted
Signal ValidationRisk ManagementLocal Affiliate ComplianceICSR SubmissionInspection ReadinessSignal DetectionAI / GxP GovernanceAggregate ReportingRegulatory Intelligence Monitoring
Action needed

Mhra update requires triage for Signal Validation, Risk Management, Local Affiliate Compliance; confirm local obligations and document follow-up actions.

Owner

Local Safety Officer

Review cadence

Immediate triage (within 1 business day), then weekly review until closure.

Evidence and confidence

Confidence: mediumSource updated: Jun 10, 2025

Primary-source confirmation recommended before operational implementation.

Full briefing

What changed

MHRA updated UK PV procedures (8 Jan 2025), published decentralised manufacture UK GVP (10 Jun 2025), and maintains UK modifications to EU GVP PDFs for UK MAHs.

Why it matters

Potential impact spans Signal Validation, Risk Management, Local Affiliate Compliance, ICSR Submission, Inspection Readiness, Signal Detection, AI / GxP Governance, Aggregate Reporting, Regulatory Intelligence Monitoring, so Local Safety Officer oversight is needed to maintain compliance readiness and evidence traceability.

Practical implication

Mhra update requires triage for Signal Validation, Risk Management, Local Affiliate Compliance; confirm local obligations and document follow-up actions.

#Country Compliance#ICSR#Signal Management#Aggregate Reporting#Risk Management#Inspection Readiness#MHRA#GVP#Country Guides#Decentralised Manufacture#Unfettered Access Route#Windsor Framework (Medicines)

Related updates for your role

RegulatorsMHRAUnited Kingdom

MHRA Class 2 Recall: ChloraPrep 2% applicators (potential sterility breach)

Regulatory action
Class 2 Medicines Recall
ChloraPrep 2% 1mL applicator · Becton Dickinson UK Ltd
Relevant for
Regulatory Intelligence LeadSignal Management Lead
Action needed

Identify and quarantine all impacted batches of ChloraPrep 2% 1mL and Frepp 2% 1.5mL applicators; return to Becton Dickinson UK Ltd.

Process impact
Signal ManagementLabeling
SOP impact

2 SOPs may need review

Urgency: HighConfidence: high
Read impact brief →
RegulatorsHealth CanadaCanada

Omnipod Insulin Management System Recall in Canada

Regulatory action
Health product recall
Omnipod Insulin Management System · Insulet Corporation
Relevant for
Regulatory Intelligence LeadSignal Management Lead
Action needed

Identify affected lots and implement recall procedures as per Health Canada guidelines.

Process impact
Signal ManagementLabeling
SOP impact

2 SOPs may need review

Urgency: HighConfidence: high
Read impact brief →
RegulatorsMedicines and Healthcare products Regulatory Agency (MHRA)United Kingdom

MHRA Largest Seizure of Unlicensed Weight Loss Medicines

Regulatory action
Enforcement Action / Public Safety Alert
Unlicensed weight loss medicines · Illicit manufacturing operation (unnamed)
Relevant for
Regulatory Intelligence LeadSignal Management Lead
Action needed

Review adverse event reports for potential links to counterfeit weight loss medicines; check product supply chain for unlicensed sources.

Process impact
Signal ManagementLabeling
SOP impact

2 SOPs may need review

Urgency: HighConfidence: high
Read impact brief →
RegulatorsEuropean Medicines Agency (EMA)European Union

EMA ETF recommends updating COVID-19 vaccines to target XFG variant for 2026/2027 campaign

Regulatory action
Regulatory Recommendation / Public Health Communication
COVID-19 vaccines · Marketing authorisation holders (various)
Relevant for
Regulatory Intelligence LeadSignal Management Lead
Action needed

Marketing authorisation holders should prepare to update their COVID-19 vaccines to target the XFG variant for the upcoming campaign; monitor for further regulatory guidance and prepare for potential strain change submissions.

Process impact
Signal ManagementLabeling
SOP impact

2 SOPs may need review

Urgency: MonitorConfidence: high
Read impact brief →